MX2010001190A - Compuesto biciclico fusionado. - Google Patents

Compuesto biciclico fusionado.

Info

Publication number
MX2010001190A
MX2010001190A MX2010001190A MX2010001190A MX2010001190A MX 2010001190 A MX2010001190 A MX 2010001190A MX 2010001190 A MX2010001190 A MX 2010001190A MX 2010001190 A MX2010001190 A MX 2010001190A MX 2010001190 A MX2010001190 A MX 2010001190A
Authority
MX
Mexico
Prior art keywords
cycloalkyl
substituent
substituted
alkyl
hydrogen
Prior art date
Application number
MX2010001190A
Other languages
English (en)
Inventor
Takayuki Kawaguchi
Hidenori Akatsuka
Nobumasa Awai
Yoichi Takahashi
Toru Iijima
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of MX2010001190A publication Critical patent/MX2010001190A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/16—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with only hydrogen or carbon atoms directly attached in positions 2 and 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/20—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona un compuesto biciclico fusionado novedoso que tiene una afinidad por un receptor del corticoide mineral (MR), mostrado por la fórmula [1]: (ver formula 1) n donde el anillo A es un anillo de benceno que tiene un sustituyente R1, fusionado a un anillo heterocíclico de 6 miembros adyacente, que tiene opcionalmente además, un sustituyente diferente de R1, R1 es un grupo alquilsulfonilamino, etc., R2 y R3 son (a) los mismos o diferentes y un átomo de hidrógeno, un grupo alquilo o un grupo arilo sustituido o no sustituido, (b) se combinan uno con el otro para formar un grupo oxo o (c) se combinan uno con el otro en su terminal, junto con el átomo de carbono adyacente para formar un grupo cicloalquilo, X es un grupo de =N-, =C(R4)- o -CH(R4)-, R4 es (a) un átomo de hidrógeno, (b) un grupo ciano, (c) un átomo de halógeno, (d) un grupo alquilo, (e) un grupo alquenilo, (f) un grupo cicloalquilo (g) un grupo alcanoilo, (h) un grupo carbamoilo o (i) un grupo cicloalquenilo, Ar es un grupo cíclico aromático sustituido opcionalmente, y una línea punteada significa la presencia o ausencia de un enlace doble, o una sal farmacéuticamente aceptable del mismo, que es útil como un agente antihipertensivo, etc.
MX2010001190A 2007-08-01 2008-07-31 Compuesto biciclico fusionado. MX2010001190A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007200264 2007-08-01
PCT/JP2008/063751 WO2009017190A1 (ja) 2007-08-01 2008-07-31 縮合二環式化合物

Publications (1)

Publication Number Publication Date
MX2010001190A true MX2010001190A (es) 2010-03-01

Family

ID=40304418

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001190A MX2010001190A (es) 2007-08-01 2008-07-31 Compuesto biciclico fusionado.

Country Status (14)

Country Link
US (2) US8258131B2 (es)
EP (1) EP2179994B1 (es)
JP (1) JP5357027B2 (es)
KR (1) KR101338813B1 (es)
CN (1) CN101809005B (es)
AU (1) AU2008283265B2 (es)
BR (1) BRPI0815037A2 (es)
CA (1) CA2693180C (es)
ES (1) ES2419254T3 (es)
MX (1) MX2010001190A (es)
PH (1) PH12013500442B1 (es)
RU (1) RU2468017C2 (es)
TW (1) TWI396540B (es)
WO (1) WO2009017190A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
EA201790723A1 (ru) 2010-07-16 2017-12-29 ЭббВи Айэленд Анлимитед Компани Способ получения противовирусных соединений
KR101774742B1 (ko) 2010-07-16 2017-09-11 애브비 아일랜드 언리미티드 컴퍼니 촉매 반응용 포스핀 리간드
CN103483237B (zh) * 2013-10-15 2015-04-08 安徽工业大学 一种双磺酸根离子液体催化制备吡咯衍生物的方法
CA2944115A1 (en) 2014-03-29 2015-10-08 Lupin Limited Sulfonamide compounds as voltage gated sodium channel modulators
AU2015282450C1 (en) 2014-06-30 2018-09-20 Astrazeneca Ab Benzoxazinone amides as mineralocorticoid receptor modulators
WO2017064121A1 (en) 2015-10-13 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
WO2018019843A1 (en) 2016-07-26 2018-02-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
CN109789147B (zh) * 2016-09-27 2022-06-24 田边三菱制药株式会社 用于治疗非酒精性脂肪性肝病的药物组合物及方法
CN112442022B (zh) * 2019-09-02 2022-05-20 承德医学院 苯并嗪-4-酮类化合物、其制备方法及医药用途
JP2023518168A (ja) 2020-03-11 2023-04-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 対象が中心性漿液性脈絡網膜症を有するか、または有する危険性があるかどうかを決定する方法。
CA3218889A1 (en) 2021-05-18 2022-11-24 Wassilios Grammenos New substituted pyridines as fungicides
BR112023023989A2 (pt) 2021-05-18 2024-01-30 Basf Se Compostos, composição, método para combater fungos fitopatogênicos e semente
EP4395785A1 (en) 2021-08-31 2024-07-10 Inserm (Institut National de la Santé et de la Recherche Scientifique) Methods for the treatment of ocular rosacea
CN115260197B (zh) * 2022-07-14 2024-03-12 深圳市国华光电研究院 一种稠环化合物及其制备方法和应用
WO2024104813A1 (en) 2022-11-14 2024-05-23 Basf Se Fungicidal mixture comprising substituted pyridines

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1060467A (zh) * 1990-09-25 1992-04-22 武田药品工业株式会社 1，3-苯并嗪衍生物、其生产方法和用途
JPH0597824A (ja) * 1990-09-25 1993-04-20 Takeda Chem Ind Ltd １，３−ベンゾオキサジン誘導体
JPH06107647A (ja) * 1992-08-12 1994-04-19 Takeda Chem Ind Ltd １，３−ベンゾオキサジン誘導体の製造法
WO1997023209A1 (fr) 1995-12-25 1997-07-03 Nissan Chemical Industries, Ltd. Agent therapeutique contre l'insuffisance cardiaque
US20030073850A1 (en) 1998-08-07 2003-04-17 Altenbach Robert J. 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use
RU2195457C1 (ru) * 2001-07-31 2002-12-27 Кубанский государственный технологический университет Замещенные 4,4-дифенил-1,2-дигидро-4н-3,1-бензоксазины, проявляющие росторегулирующую и антистрессовую активность
AU2003241482A1 (en) * 2002-05-16 2003-12-02 Cytovia, Inc. Substituted 4h-chromenes, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2005037830A1 (en) 2003-10-10 2005-04-28 Wyeth Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands
EP1844768A1 (en) 2005-01-19 2007-10-17 Dainippon Sumitomo Pharma Co., Ltd. Aromatic sulfone compound as aldosterone receptor modulator
US7598261B2 (en) * 2005-03-31 2009-10-06 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
TWI385161B (zh) 2006-02-02 2013-02-11 Mitsubishi Tanabe Pharma Corp 含氮雜雙環化合物
JP5099814B2 (ja) 2006-02-02 2012-12-19 田辺三菱製薬株式会社 含窒素複素二環式化合物

Also Published As

Publication number Publication date
EP2179994B1 (en) 2013-06-26
US8258131B2 (en) 2012-09-04
BRPI0815037A2 (pt) 2015-03-17
PH12013500442A1 (en) 2015-09-07
KR20100046230A (ko) 2010-05-06
AU2008283265A1 (en) 2009-02-05
CA2693180A1 (en) 2009-02-05
US20100204218A1 (en) 2010-08-12
AU2008283265B2 (en) 2012-05-24
CA2693180C (en) 2012-11-20
US8410166B2 (en) 2013-04-02
KR101338813B1 (ko) 2013-12-06
EP2179994A4 (en) 2010-08-25
PH12013500442B1 (en) 2015-09-07
RU2468017C2 (ru) 2012-11-27
EP2179994A1 (en) 2010-04-28
TWI396540B (zh) 2013-05-21
JP5357027B2 (ja) 2013-12-04
TW200914026A (en) 2009-04-01
JPWO2009017190A1 (ja) 2010-10-21
US20130029979A1 (en) 2013-01-31
WO2009017190A1 (ja) 2009-02-05
CN101809005A (zh) 2010-08-18
RU2010107277A (ru) 2011-09-10
ES2419254T3 (es) 2013-08-20
CN101809005B (zh) 2013-05-01

Similar Documents

Publication Publication Date Title
MX2010001190A (es) Compuesto biciclico fusionado.
PH12014501708A1 (en) Novel anti-platelet agent
MX2010008039A (es) Compuestos triciclicos que tienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que contienen los mismos.
MX2009004920A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1.
TW200718692A (en) Dihydrobenzofuran derivatives and uses thereof
WO2009057784A1 (ja) 複素環化合物
MEP0508A (xx) Derivati pirimidina
MX2014000452A (es) Derivados de azabencimiazol que tiene actividad activadora de la proteina cinasa activada monofosfato de denosina (ampk).
MXPA04005350A (es) Compuesto de dibencilamina, y uso medicinal del mismo.
ZA200609261B (en) Fused quinoline derivative and use thereof
MX2009010024A (es) Nuevo compuesto de adenina.
MX2010009372A (es) Derivado heterociclico fusionado y su uso.
TW200606152A (en) Piperidine compound and process for preparing the same
UY30897A1 (es) Derivados de pentafluorotiobenzamidoacetonitrilo, composiciones conteniéndolos y aplicaciones
PH12016502358B1 (en) Novel pyrrolidine compound and application as melanocortin receptor agonist
WO2008126901A1 (ja) 含窒素複素環化合物およびそれを含有する医薬組成物
DE602006011725D1 (de) 3-triazolylthioalkyl-3-azabicyclo ä3.1.0ühexane und ihre verwendung als liganden des dopamin-d3-rezeptors
WO2008051533A3 (en) Benzimidazole compounds
TW200609218A (en) Bicyclic compounds
IN2012DN00770A (es)
MY197742A (en) Morphinan derivative
MX345544B (es) Derivados de triazol como ligandos para receptores de acido gamma-aminobutirico (gaba).
IN2012DN00768A (es)
WO2006075023A3 (en) Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
MX2019004107A (es) Derivado heterociclico nitrogenado biciclico y composicion farmaceutica que lo contiene.

Legal Events

Date Code Title Description
FG Grant or registration